Geron (GERN) FDA Announcement summary

Introduction and purpose

• RYTELO (imetelstat) received FDA approval as the first and only telomerase inhibitor for adults with low- to intermediate-1-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia unresponsive or ineligible for ESAs, addressing a high unmet need for patients who often become dependent on red blood cell transfusions.

• The approval was discussed in conference calls outlining prescribing information, market opportunity, launch plans, and post-marketing requirements.

Details of approval or decision

• Approved for adults with low- to intermediate-1-risk MDS and transfusion-dependent anemia, including ESA-ineligible, relapsed, or refractory patients, regardless of ring sideroblast status.

• Indicated for patients requiring four or more red blood cell units over eight weeks.

• No contraindications, boxed warnings, or REMS program; two dosage forms approved (47 mg and 188 mg vials).

• RYTELO is administered intravenously every four weeks, aligning with routine blood count monitoring.

Impact on industry and stakeholders

• RYTELO is expected to transform the treatment paradigm for low-risk MDS patients with transfusion-dependent anemia, addressing a high unmet need for approximately 13,200 U.S. patients, with 84% expected to be covered by Medicare.

• Launch targets 8,000 healthcare professionals and 2,200 accounts, with 70% of patients treated in community settings.

• Comprehensive support programs for patients, prescribers, and payors to facilitate access and affordability.

• Wholesale acquisition cost: $9,884 for 188 mg vial, $2,471 for 47 mg vial.

• Geron is conducting additional trials in other hematologic malignancies, including myelofibrosis.